Serum Concentrations of Pentraxin3 in Patients With Acute Coronary Syndrome: A Case-Control Study

Cardiovascular diseases are the first and the most common cause of death in Iran. Pentraxin3 (PTX3) is an inflammatory marker that increases in patients with acute myocardial infarction. This study aimed to compare the PTX3 level among patients with acute coronary syndrome (ACS).
 
The present study enrolled 130 patients with ACS and 82 subjects as the control group. Within 12 hours of the onset of chest pain, 5 mL of blood was obtained from the antecubital vein. Then, serum was separated by centrifugation and stored at –70 °C until the measurement of PTX3. The level of PTX3 was measured using an enzyme-linked immunosorbent assay kit. Data were recorded and analyzed by SPSS version 16.0. A P-value of less than 0.05 was considered statistically significant.
 
The distribution of age, sex, diabetes mellitus, hypertension, and hyperlipidemia was similar in both the ACS and control groups, but it was not similar for smoking. Serum PTX3 was significantly higher in the ACS group. The serum PTX3 level was higher in the subgroup with ST-segment elevation myocardial infarction than in the subgroups with unstable angina pectoris, stable angina pectoris, and noncardiac diseases. Additionally, patients with unstable angina pectoris had higher PTX3 than those with stable angina pectoris and noncardiac diseases.
 
Our results suggest that PTX3 may be released by systemic inflammation at the very onset of acute myocardial infarction. (Iranian Heart Journal 2021; 22(3): 64-73)